Shippeo Launches Second Edition of Visibility Now!, the Premier Event for Supply Chain & Transportation Visibility
10.11.2021 11:15:00 EET | Business Wire | Press release
Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the second edition of its customer community event Visibility Now! in partnership with Savoye, TESISQUARE®, and Siemens Digital Logistics. The hybrid event will take place both online and in-person in Paris on November 17 and offer a unique experience for all participants no matter where they are. From keynotes to customer testimonials and workshops and expert sessions, participants will have the chance to discover product insights and benefit from the expert’s points of view.
With covid border restrictions, container and driver shortages as well as the recent Suez Canal obstruction, now is the time for organizations to build resilient supply chains and visibility as a key enabler.
The event will include speakers from leading international organizations who will share their experiences on working with visibility solutions, outlining the critical roles they play in their digital transformation initiatives, and covering topics such as supply chain automation, global supply chain management, customer-centric approach and product innovation. Participants will have the opportunity to:
- Hear industry leaders discuss their experiences and best practices, including speakers from Renault Group, Coca-Cola HBC, DHL Freight, Nexans, Leroy Merlin, Philip Morris International, and Magnus Logistics
- Listen to top experts covering the latest trends, innovations, and guidelines to ensure transportation visibility project success such as Dr. John Gattorna, Siemens Digital Logistics, Savoye and TESISQUARE®
- Enjoy complimentary access to exclusive recorded sessions to dive deeper into trending topics on supply chain management and visibility
- Meet and engage with Shippeo’s team, alongside other Shippeo users and industry peers throughout the day
Global Supply Chain thought leader, Dr. John Gattorna, will share insights on designing future supply chains with embedded resilience, the challenges of operating global supply chain networks, and embracing multi-modal transportation as an integral part of future supply chains. He will also touch on the future role of 3PLs and 4PLs as genuine partners in the extended supply chain.
The event will include a live 90-minute plenary live show, broadcast from Paris in a dynamic and interactive format where participants will discover the latest insights, trends, and innovations related to supply chain and transportation visibility across a number of industry sectors. Several workshops and expert sessions will be held on demand for a deep dive into trending topics and best practices. These interactive workshops will provide an opportunity for participants to interact with other market leaders facing similar challenges and hear more about the latest news, insights, and product innovations in supply chain and transportation visibility from Shippeo experts.
“In the midst of supply chain disruptions, businesses have come to realize the value of real-time visibility and the need to take action, and further engage in digital transformation processes. We’re delighted to showcase the must-attend transportation visibility event and offer participants a place where they can hear from top industry experts, interact with other shippers, carriers, and logistics service providers from across the ecosystem to share and discover new ways to leverage visibility,” says Lucien Besse, COO of Shippeo.
The live show will stream from 1.30 pm on Wednesday 17th November. More information about the agenda, speakers, and how to register for the free event is available at shippeo.com/visibilitynow
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 850+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 25 million shipments per year across 74 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005610/en/
Contact information
Audrey Emanuel, audrey.emanuel@shippeo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom